AEON Biopharma (AEON)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	537.00 k	537.00 k	537.00 k	537.00 k	537.00 k	537.00 k
Cash burn (monthly)	340.33 k	385.08 k	2.06 mm	13.24 mm	(no burn)	1.60 mm
Cash used (since last report)	949.51 k	1.07 mm	5.74 mm	36.95 mm	n/a	4.47 mm
Cash remaining	-412.51 k	-537.36 k	-5.20 mm	-36.41 mm	n/a	-3.94 mm
Runway (months of cash)	-1.2	-1.4	-2.5	-2.7	n/a	-2.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

AEON institutional ownership history Ownership history

17.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	14	22	-36.4%
Opened positions	10	13	-23.1%
Closed positions	18	6	+200.0%
Increased positions	0	2	EXIT
Reduced positions	3	3	–

13F shares	Current	Prev Q	Change
Total value	3.93 bn	1.47 bn	+167.0%
Total shares	6.32 mm	3.22 mm	+96.5%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Polar Asset Management Partners	3.68 mm	$3.27 bn	NEW
Strathspey Crown	2.03 mm	$14.26 mm	0.0%
Ikarian Capital	257.98 k	$270.88 mm	NEW
Davidson Kempner Capital Management	90.05 k	$94.56 mm	NEW
STT State Street	60.95 k	$64.00 mm	NEW
LMR Partners	54.96 k	$57.71 mm	-78.0%
Millennium Management	50.99 k	$53.53 mm	NEW
Jane Street	23.27 k	$24.44 mm	-43.0%
BAC Bank of America	23.15 k	$24.31 mm	NEW
Y-Intercept	20.94 k	$21.99 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Polar Asset Management Partners	3.68 mm	+3.68 mm	NEW
Ikarian Capital	257.98 k	+257.98 k	NEW
LMR Partners	54.96 k	-195.04 k	-78.0%
Wolverine Asset Management	0.00	-189.15 k	EXIT
Q Global Advisors	0.00	-132.23 k	EXIT
Davidson Kempner Capital Management	90.05 k	+90.05 k	NEW
Calamos Advisors	0.00	-83.33 k	EXIT
GS The Goldman Sachs Group, Inc.	0.00	-79.53 k	EXIT
Ubs Oconnor	0.00	-75.00 k	EXIT
Kim	0.00	-63.36 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

AEON insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
31 Aug 24	Palmisano Robert J	Class A Common Stock	Grant	Acquire A	No	No	0	36,021	0.00	36,021
31 Aug 24	Palmisano Robert J	Stock Option Class A Common Stock	Grant	Acquire A	No	No	0.83	96,210	79.85 k	96,210
31 Aug 24	Alexander Blair Wilson	Class A Common Stock	Grant	Acquire A	No	No	0	180,110	0.00	261,538
31 Aug 24	Alexander Blair Wilson	Stock Option Class A Common Stock	Grant	Acquire A	No	No	0.83	480,631	398.92 k	480,631
31 Aug 24	Chad Oh	Class A Common Stock	Grant	Acquire A	No	No	0	192,117	0.00	292,545
31 Aug 24	Chad Oh	Stock Option Class A Common Stock	Grant	Acquire A	No	No	0.83	512,673	425.52 k	512,673
31 Aug 24	Marc Forth	Class A Common Stock	Grant	Acquire A	No	No	0	470,692	0.00	750,547
31 Aug 24	Marc Forth	Stock Option Class A Common Stock	Grant	Acquire A	No	No	0.83	1,256,062	1.04 mm	1,256,062
31 Aug 24	Jost Fischer	Class A Common Stock	Grant	Acquire A	No	No	0	36,021	0.00	96,785
31 Aug 24	Jost Fischer	Stock Option Class A Common Stock	Grant	Acquire A	No	No	0.83	96,210	79.85 k	96,210

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

AEON Biopharma Q3 2024 GAAP EPS $(0.16), Inline

13 Nov 24

AEON Biopharma (AMEX:AEON) reported quarterly losses of $(0.16) per share which met the analyst consensus estimate.

12 Health Care Stocks Moving In Wednesday's Intraday Session

9 Oct 24

12 Health Care Stocks Moving In Friday's Intraday Session

4 Oct 24

HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $5 Price Target

1 Oct 24

Press releases

From Benzinga Pro

AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting

30 Sep 24

– Company is aligned with the FDA on next steps for a 351(k) regulatory pathway to approval for ABP-450 (prabotulinumtoxinA) as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product – –